BOARD OF DIRECTORS

Our Board consists of seven Directors, comprising four executive Directors and three independent non-executive Directors. The following table sets forth the key information about our Directors as of the Latest Practicable Date.

Name	Age	Positions	Roles and responsibilities	Date of first joining our Group	Date of first appointment as a Director
Mr. CHEN Bang (陳邦)	60	Chairman of the Board and executive Director	Responsible for leading the strategic planning, business direction and overall management of our Group	January 2003	January 2003
Mr. LI Li (李力)	60	Vice chairman of the Board, executive Director and general manager	Responsible for daily operations, strategic planning, and overall management of our Group	January 2003	January 2003
Dr. WU Shijun (吳士君)	53	Executive Director, deputy general manager and Board secretary	Responsible for capital planning and investor relations of our Group	November 2004	October 2018
Mr. ZHOU Jianjun (周建軍)	55	Executive Director	Responsible for administrative management, support, and maintenance of the Group	January 2003	November 2025
Mr. GAO Guolei (高國壘)	48	Independent non-executive Director	Responsible for providing independent advice and judgment to our Board	November 2022	November 2022
Dr. TIAN Suhua (田素華)	56	Independent non-executive Director	Responsible for providing independent advice and judgment to our Board	November 2025	November 2025
Ms. PENG Hui (彭慧)	39	Independent non-executive Director	Responsible for providing independent advice and judgment to our Board	May 2026	May 2026

Executive Directors

Mr. CHEN Bang (陳邦), aged 60, is the chairman of the Board and an executive Director of our Group. He is mainly responsible for leading the strategic planning, business direction and overall management of our Group.

Mr. Chen has been serving as the director at Aier Investment since January 2003. He founded our Company in January 2003 and then was appointed as a Director.

Mr. Chen is a recipient of numerous accolades. His key recognitions include (i) being selected as the Sixth National Outstanding Builder of Socialism with Chinese Characteristics among Non-Public Economic Figures (第六屆全國非公有制經濟人士優秀中國特色社會主義事業建設者) in July 2025, (ii) being selected as the Second New Hunan Contribution Award Outstanding Individual (第二屆新湖南貢獻獎先進個人) in December 2023, (iii) being selected as the Fourth Hunan Province Outstanding Builder of Socialism with Chinese Characteristics among Non-Public Economic Figures (第四屆湖南省非公有制經濟人士優秀中國特色社會主義事業建設者) in 2021, and (iv) being selected as the Outstanding Individual in the Fight Against COVID-19 in Hunan Province (湖南省抗擊新冠肺炎疫情先進個人) in 2020.

Mr. Chen obtained a master of business administration degree from Hunan University (湖南大學) in the PRC in December 2007.

Mr. LI Li (李力), aged 60, is a vice chairman of the Board, executive Director and general manager of our Group. He is mainly responsible for daily operations, strategic planning, and overall management of our Group.

Mr. Li has served as a director since the establishment of the Group.

Mr. Li is a recipient of numerous accolades. His key recognitions include (i) being selected as the Hunan Outstanding Entrepreneur (湖南省優秀企業家) by Hunan Federation of Enterprises and Industrial Economics in 2022, (ii) being selected as the Leading Figure in Private Medical Industry (民營醫療行業領軍人物) in 2021, (iii) being named to the 2020 Forbes China Best CEO List, and (iv) being recognized as a Category-A Talent of Changsha Municipality in 2023.

Mr. Li graduated with a law major from Xiang Tan University (湘潭大學) in the PRC in November 1996.

Dr. WU Shijun (吳士君), aged 53, is an executive Director, a deputy general manager and Board secretary of our Group. He is mainly responsible for capital planning and investor relations of our Group.

From November 2004 to March 2018 (excluding December 2011 to July 2012), Dr. Wu held various key positions, including a manager of the strategy department, an assistant to the chairman of the Board and the Board secretary of our Group. From March 2018, Dr. Wu was promoted to a deputy general manager and concurrently served as the Board Secretary. Since October 2018, he has served as a director, a vice president and the Board Secretary of our Group.

Dr. Wu is a recipient of numerous accolades. His key recognitions include (i) being awarded 5A in the Board Secretary Performance Evaluation by the Listed Companies Association of China for four consecutive times since 2022, (ii) being selected in the New Fortune Golden Board Secretary Hall of Fame (新財富金牌董秘名人堂) by New Fortune in 2021, (iii) being selected in the Hunan Listed Company Outstanding Board Secretary Hall of Fame (湖南省上市公司優秀董秘名人堂) by the Hunan Listed Companies Association in 2019, (iv) as a member of the 10th Listing Committee of the Shenzhen Stock Exchange, and (v) being recognized as a Category-C Talent of Changsha Municipality in 2022.

Dr. Wu obtained a Ph. D. in world economics from Fudan University (復旦大學) in the PRC in July 2002.

Mr. ZHOU Jianjun (周建軍), aged 55, is an executive Director of our Group as our employee representative Director. He is mainly responsible for administrative management, support, and maintenance of the Group.

Mr. Zhou joined our Group in January 2003 and has been serving as a logistics supervisor, where he is mainly responsible for formulating the Company's logistics management systems, standards and budget plans and coordinating logistics support requirements across all departments. Mr. Zhou was selected as our employee representative Director in November 2025.

Mr. Zhou does not hold a college degree.

Independent Non-executive Directors

Mr. GAO Guolei (高國壘), aged 48, has been our independent non-executive Director since November 2022. He is mainly responsible for providing independent advice and judgment to our Board.

From July 2007 to April 2015, he served as the board secretary at Canature Health Technology Group Co., Ltd. (開能健康科技集團股份有限公司), previously known as Shanghai Kaineng Shanghai Canature Environmental Products Co., Ltd. (上海開能環保設備股份有限公司), "**Shanghai Canature**", a company whose shares are listed on the Shenzhen Stock Exchange (stock code: 300272).

In addition to his directorship at our Company, Mr. Gao also holds concurrent directorships in other companies, including (i) as a director and chairman of the board at Shanghai Zhanghe Investment Co., Ltd. (上海章和投資有限公司) since September 2018, and (ii) as an independent director at Shanghai OBiO Technology (Group) Corp., Ltd. (上海和元生物技術(集團)股份有限公司), a company whose shares are listed on the Shanghai Stock Exchange (stock code: 688238).

Mr. Gao is a recipient of numerous accolades. His key recognitions include (i) being selected as the Listed Company Person of the Year (上市公司年度人物) by the Development Research Center of the State Council, and (ii) being selected as the Golden Board Secretary (金牌董秘).

On June 23, 2016, the Department of ChiNext Market Supervision of the Shenzhen Stock Exchange issued a regulatory letter (the "**Regulatory Letter**") to the board of directors of Shanghai Canature in relation to its provision of financial assistance in an aggregate amount of RMB16 million in two investee companies in 2014 and 2015, for which Shanghai Canature failed to comply with the requisite board review procedures and disclosure obligation. The Regulatory Letter mentioned that the Shenzhen Stock Exchange considers Mr. Gao and two succeeding board secretaries of Shanghai Canature to be mainly responsible for the breach of the relevant disclosure obligation.

As confirmed by Mr. Gao, (i) he resigned as the board secretary of Shanghai Canature in April 2015, (ii) he did not personally participate in the provision of financial assistance and (iii) he was not aware of the Regulatory Letter and was not contacted by Shanghai Canature or the Shenzhen Stock Exchange in relation to the Regulatory Letter.

Notwithstanding the Regulatory Letter, the Directors are of the view that Mr. Gao has the experience, knowledge and skills required of a director of a listed company and is therefore suitable to be a Director pursuant to Rules 3.08 and 3.09 of the Listing Rules, after taking into account the following:

- Based on Mr. Gao' representation, he was not aware of and did not participate in Shanghai Canature's provision of financial assistance in 2014 and 2015 personally.

- There was no reference as to the integrity of Mr. Gao in the Regulatory Letter.

- According to the PRC Legal Adviser, (i) the Regulatory Letter was a self-regulatory measure as part of the Shenzhen Stock Exchange's post-vetting review and does not constitute or result in any administrative penalty and (ii) the Regulatory Letter does not disqualify Mr. Gao as a director of public companies in the PRC.

- As confirmed by Mr. Gao and based on the background search of Mr. Gao, there have been no similar incidents being reported other than the incident identified in the Regulatory Letter.

- Mr. Gao was appointed as an independent director of Obio Technology (Shanghai) Corp., Ltd. (和元生物技術(上海)股份有限公司) which is listed on the Shanghai Stock Exchange (stock code: 688238), and a proposed independent non-executive director of Healife Group Co., Ltd. (上海萬怡醫學科技股份有限公司), which indicate Mr. Gao was not disqualified as a director of public companies in the PRC and Mr. Gao's extensive experience in serving as an independent director of listed companies.

- Mr. Gao has endeavoured to keep himself educated and informed of rules of corporate governance, and enhance his familiarity with relevant legislation, rules and regulation. He attended a training of directors' general duties under the Listing Rules and the laws of Hong Kong conducted by the Company's Hong Kong legal adviser in May 2026.

Mr. Gao obtained a bachelor's degree in trade economics from East China University of Political Science and Law (華東政法大學) in the PRC in July 2001 and was a senior visiting scholar at Columbia University in the United States.

Dr. TIAN Suhua (田素華), aged 56, has been our independent non-executive Director since November 2025. He is mainly responsible for providing independent advice and judgment to our Board.

Since 2009, Dr. Tian has been working at the School of Economics of Fudan University (復旦大學經濟學院), where he currently holds the positions of the professor, a doctoral supervisor, primarily engaged in research and teaching. In addition to his directorship at our Company, Dr. Tian has been serving as an independent director at Hundsun Technologies Inc. (恒生電子股份有限公司), a company whose shares are listed on the Shanghai Stock Exchange (stock code: 600570) since March 2024.

Dr. Tian is a recipient of numerous accolades. His key recognitions include (i) obtaining National First-Class Undergraduate Courses (國家一流本科課程) by the Ministry of Education, (ii) obtaining the Second Prize of National Teaching Achievement Award (國家級教學成果獎二等獎) by the Ministry of Education, and (iii) obtaining the Special Prize for Teaching Achievement in Shanghai (上海市教學成果特等獎) by the Shanghai Municipal Education Commission.

Dr. Tian obtained a bachelor's degree in industrial foreign trade from Nanjing University of Science and Technology (南京理工大學) (formerly known as Huadong Mechanics College (華東工學院)) in the PRC in June 1992, a master's degree in international trade and a Ph. D. in world economics from Fudan University (復旦大學) in the PRC in June 1999 and June 2002, respectively.

Ms. PENG Hui (彭慧), aged 39, has been our independent non-executive Director since May 18, 2026. She is mainly responsible for providing independent advice and judgment to our Board.

From October 2008 to September 2011, Ms. Peng served as a senior auditor of Ernst & Young. In December 2011, she then joined Concord Medical Services Holdings Limited, a company whose shares are listed on the New York Stock Exchange (stock code: CCM), as a senior financial manager until July 2014. She worked as a financial manager at Guangdong Dongfang Precision Technology Co., Ltd. (廣東東方精工科技股份有限公司) from September 2014, a company whose shares are listed on the Shenzhen Stock Exchange (stock code: 002611). Ms. Peng then worked as a deputy general manager of the finance department at RENZE HARVEST INTERNATIONAL LIMITED (former known as Glory Sun Financial Group Limited), a company whose shares are listed on the Stock Exchange (stock code: 1282) from September 2016 to April 2020. From April 2020 to October 2021, she served as a deputy general manager of Pak Tak International Limited, a company whose shares are listed on the Stock Exchange (stock code: 2668).

In addition to her directorship at our Company, Ms. Peng also holds concurrent positions in other companies, including (i) as the chief financial officer at Edensoft Holdings Limited, a company whose shares are listed on the Stock Exchange (stock code: 1147) since November 2021 and its company secretary since July 2023, and (ii) as an independent director at Busy Ming Group Co., Ltd., a company whose shares are listed on the Stock Exchange (stock code: 1768) since January 2026.

Ms. Peng obtained a bachelor's degree in international economics and trade from Guangdong University of Foreign Studies (廣東外語外貿大學) in PRC in June 2008 and a master's degree in business administration from the University of Hong Kong in PRC in November 2018. She is a fellow member of the Hong Kong Institute of Certified Public Accountants (香港會計師公會) and the Chinese Institute of Certified Public Accountants (中國註冊會計師協會), and holds the certificates of Certified Public Accountant (CPA) in both Chinese Mainland and Hong Kong.

SENIOR MANAGEMENT

Our senior management is responsible for the day-to-day management of our business. The following table sets forth the key information about our senior management as of the Latest Practicable Date.

Name	Age	Positions	Roles and Responsibilities	Date of first joining our Group	Date of first appointment as a senior management
Mr. LI Li (李力)	60	Vice chairman of the Board, executive Director and general manager	Responsible for daily operations, strategic planning, and overall management of our Group	January 2003	December 2007
Mr. HAN Zhong (韓忠)	60	Deputy general manager	Responsible for the operation and management of Aier Eye Hospitals in Hubei and Henan provinces	May 2005	December 2007
Dr. WU Shijun (吳士君)	53	Executive Director, deputy general manager and Board secretary	Responsible for capital planning and investor relations of our Group	November 2004	April 2013
Mr. LIU Duoyuan (劉多元)	64	Deputy general manager	Responsible for directing and overseeing the financial management	August 2004	December 2012
Dr. TANG Shibo (唐仕波)	65	Deputy general manager	Responsible for the overall clinical management and strategic development of the ophthalmic medical services of our Group	August 2012	August 2012
Dr. YANG Zhikuan (楊智寬)	61	Deputy general manager	Responsible for the research and development and medical quality oversight of the optometry and pediatric ophthalmology services of our Group	March 2011	December 2016
Ms. WANG Lihua (王麗華)	52	Deputy general manager	Responsible for overseeing human resources management of the Group	November 2008	December 2016
Ms. FENG Jun (馮珺)	46	Deputy general manager	Responsible for the overall business operations and the operations and management of Aier Eye Hospitals in Shanghai	July 2003	April 2020
Ms. ZHANG Yan (張艷)	57	Deputy general manager	Responsible for the operation and management of Aier Eye Hospitals in Hunan, Jiangxi, Guizhou and Xinjiang provinces	January 2003	September 2022
Ms. ZHANG Yongmei (張詠梅)	45	Deputy general manager	Responsible for the overseas major investment projects, the overseas business development, as well as external cooperation and exchanges of the Group	June 2014	November 2023

Name	Age	Positions	Roles and Responsibilities	Date of first joining our Group	Date of first appointment as a senior management
Ms. MO Qiwen (莫綺雯)	46	Chief financial officer	Responsible for directing financial and accounting management	February 2011	November 2025

Mr. LI Li (李力), aged 60, is a vice chairman of the Board, executive Director and general manager of our Group. For his biography, see "— Board of Directors — executive Directors" in this section.

Mr. HAN Zhong (韓忠), aged 60, is a deputy general manager of the Group. He is mainly responsible for the operation and management of Aier Eye Hospitals in Hubei and Henan provinces.

Mr. Han has been with our Group since November 2004. He initially served as an assistant to the chairman of the Board, the chief financial officer and the secretary of the Board from May 2005 to January 2012. From December 2007 to November 2025, Mr. Han served as a Director of the Company, participating in decision-making and contributing to the formulation of the Company's strategic direction. In January 2012, Mr. Han was promoted to a deputy general manager of the Company, a position he has held to the present. Concurrently, from January 2012 to June 2025, he served as the General Manager of the Hubei Regional Division. From December 2016 to June 2025, he also served as the General Manager of the Henan Provincial Division, further expanding his regional management responsibilities. From November 2023 to June 2025, he additionally served as the General Manager of the Hubei-Henan Greater Regional Division.Since June 2025, Mr. Han has served as the chairman of the management committee of the Hubei-Henan Region, continuing to oversee the strategic planning and operational management of the Company's business in these key markets.

Mr. Han graduated with an accounting major from Guanghua School of Management of Peking University (北京大學光華管理學院) in the PRC in July 1998.

Dr. WU Shijun (吳士君), aged 53, is an executive Director, a deputy general manager and Board secretary of our Group. For his biography, see "— Board of Directors — executive Directors" in this section.

Mr. LIU Duoyuan (劉多元), aged 64, is a deputy general manager of our Group. He is mainly responsible for directing and overseeing the financial management.

Mr. Liu joined our Group in August 2004 as a chief accountant of the financial management center until December 2012, responsible for overseeing day-to-day financial operations and reporting. He served as a deputy chief financial officer from May 2011 to January 2012 and then was promoted to a chief financial officer, a position he held until November 2025, Mr. Liu has been a deputy general manager of our Group since December 2016. Since July 2024, Mr. Liu has also served as a graduate industry mentor at the Graduate School of Hunan University (湖南大學研究生學院).

Mr. Liu graduated with an accounting major from Hunan University (湖南大學) (formerly known as Hunan Finance and Economics College (湖南財經學院)) in the PRC in July 1989. Mr. Liu was honored with the Golden Lotus Chief Financial Officer Hall of Fame (金芙蓉財務總監名人堂) by the Hunan Province Listed Companies Association (湖南省上市公司協會) in December 2024.

Dr. TANG Shibo (唐仕波), aged 65, is a deputy general manager of our Group. He is mainly responsible for the overall clinical management and strategic development of the ophthalmic medical services of our Group.

Prior to joining our Group, Dr. Tang served as a deputy head and a deputy dean at the Zhongshan Ophthalmic Centre of Sun Yat-sen University (中山大學中山眼科中心) from 1999 to 2012. He then joined our Group in August 2012 as a deputy general manager and the chief, dean within our Group.

Dr. Tang is a recipient of numerous accolades. He is a National Grade-2 Professor. His key recognitions include (i) obtaining the China Industry-University-Research Cooperation Innovation and Progress Award (中國產學研合作創新與進步獎) by the China Association for the Promotion of Industry-University-Research Cooperation (中國產學研合作促進會), (ii) obtaining the Best National Committee Member Award of the 13th Annual Congress of the Ophthalmologist Branch of the Chinese Medical Doctor Association (第十三屆中國醫師協會眼科醫師分會年會最佳全國委員), (iii) obtaining the First Prize of Chinese Medical Science and Technology Award (中國醫學科技獎一等獎) by the Chinese Medical Association (中華醫學會), (iv) obtaining the Special Government Allowance of PRC's State Council (國務院政府特殊津貼), and (v) being selected as the Humboldt Research Fellowship (德國洪堡基金獲得者).

Dr. Tang obtained a bachelor's degree in medicine from Sun Yat-sen University (中山大學) (formerly known as Zhongshan Medical University (中山醫科大學)) in the PRC in August 1983. He also obtained a Ph. D. in ophthalmology from University of Munich (德國慕尼黑大學) in Germany in May 1992.

Dr. YANG Zhikuan (楊智寬), aged 61, is a deputy general manager of our Group. He is mainly responsible for the research and development and medical quality oversight of the optometry and pediatric ophthalmology services of our Group.

In December 2016, he joined our Group and has been serving as a deputy general manager of the Company.

In addition to his position in our Group, Dr. Yang also holds concurrent positions in various professional institutions, including serving (i) as leader of the Optometry Group of the Ophthalmology Branch of the Chinese Medical Association (中華醫學會), (ii) as a deputy chief member of the Optometry Professional Committee of the Ophthalmologist Branch of the Chinese Medical Doctor Association (中國醫師協會), (iii) as a director of Hunan Optometry Engineering Center (湖南省觀光工程中心), (iv) as a director of Hunan Aier Optometry Research Institute (湖南愛爾眼視光研究所), (v) as a chairman of the Visual Health Branch of the China International Exchange and Promotion Association for Medical and Healthcare (中國醫療保健國際交流促進會), (vi) as a chairman of Hunan Optometry Society (湖南省視光學會), and (vii) as an editorial board member of Chinese Journal of Optometry and Visual Science (中華眼視光及視覺科學雜誌) and (viii) as a research fellow and deputy director at Zhongshan Ophthalmic Center, Sun Yat-sen University.

Dr. Yang is a recipient of numerous accolades. His key recognitions include (i) being awarded the National Teaching Achievement Award (國家級教學成果獎) by Ministry of Education in July 2023, (ii) being awarded the Special Government Allowance (政府特殊津貼) by the State Council in December 2023, and (iii) being awarded the First Prize of the Guangdong Provincial Science and Technology Progress Award in 2012.

Dr. Yang obtained a Ph. D. in ophthalmology from Tongji Medical College of Huazhong University of Science and Technology (華中科技大學同濟醫學院) in the PRC in June 1998.

Ms. WANG Lihua (王麗華), aged 52, is a deputy general manager of our Group. She is mainly responsible for overseeing human resources management of the Group.

Ms. Wang has been with our Group since November 2008. She initially served as a deputy director of the general manager's office from November 2008 to January 2009, where she was mainly responsible for facilitating the implementation of decisions made by the general manager and senior management, as well as providing comprehensive coordination for the Company's business operations and management. From January 2009 to May 2011, she served as a manager of the human resources department, overseeing the department's daily operations and supporting the implementation of the Company's business strategy through talent recruitment, development, and retention. In May 2011, she was promoted to the director of the human resources department, a position she held until December 2023. Since December 2016, she served as a deputy general manager of our Company.

Ms. Wang obtained a bachelor's degree in accounting from Hunan University (湖南大學) (formerly known as Hunan Finance and Economics College (湖南財經學院)) in the PRC in June 1996. Ms. Wang was recognized as a Changsha High-Caliber Personnel (Level C) (長沙市高層次人才(C類)) by the Changsha Municipal Committee Talent Work Leading Group Office in August 2022.

Ms. FENG Jun (馮珺), aged 46, is a deputy general manager of our Group. She is mainly responsible for the overall business operations and the operations and management of Aier Eye Hospitals in Shanghai.

She initially served as the head of Online Marketing within the marketing department from July 2003 to October 2011, where she was mainly responsible for developing and implementing the digital marketing strategies and expanding its online presence. She was then promoted to serve as a manager of the marketing department, a position she held until October 2011. From November 2011 to August 2020, Ms. Feng served as the head of the refractive surgery business division. In April 2020, Ms. Feng was promoted to a deputy general manager, a position she has held to the present. Concurrently, from August 2020 to March 2025, she served as the head of the cataract and glaucoma business division, overseeing the strategic planning and operational management of these key ophthalmic sub-specialties. Since June 2024, Ms. Feng has also served as the chairman of the management committee of the Shanghai region, responsible for the strategic direction and business operations of the Shanghai regional market. Since March 2025, she has additionally served as the head of the marketing center, overseeing the overall marketing strategy and brand management.

Ms. Feng obtained a master's degree in business administration from Hunan University (湖南大學) (formerly known as Hunan Finance and Economics College (湖南財經學院)) in the PRC in June 2014.

Ms. ZHANG Yan (張艷), aged 57, is a deputy general manager of our Group. She is mainly responsible for the operation and management of Aier Eye Hospitals in Hunan, Jiangxi, Guizhou and Xinjiang provinces.

She is a recipient of numerous accolades. Her key recognitions include (i) being recognized as Hunan's Most Beautiful Poverty Alleviation Figure (湖南省最美扶貧人物) by the Hunan Provincial Poverty Alleviation Office, and (ii) being awarded as an Outstanding Deputy to the 14th and 15th Changsha Municipal People's Congress (長沙市第十四及十五屆優秀人大代表) by the Changsha Municipal People's Congress.

Ms. Zhang obtained a bachelor's degree in Chinese language and literature from Changsha Vocational and Technical Normal College (長沙職業技術師範專科學校) in the PRC in July 1991.

Ms. ZHANG Yongmei (張詠梅), aged 45, is a deputy general manager of our Group. She is mainly responsible for the overseas major investment projects, the overseas business development, as well as external cooperation and exchanges of the Group.

In addition to her position in our Company, she also holds concurrent positions in our subsidiaries. Since August 2017, Ms. Zhang has been a vice chairman of the board of CLINICA-BAVIERA SA, whose shares are listed on the Madrid Stock Exchange (stock code: CBAV). She also has been a non-executive and non-independent director of ISEC Healthcare Ltd., whose shares are listed on the Singapore Stock Exchange (stock code: 40T), since December 2019.

Ms. Zhang obtained a bachelor's degree in international trade from Tongji University (同濟大學) in the PRC in July 2002, and a master's degree in business administration from Fudan University (復旦大學) in the PRC in January 2014.

Ms. MO Qiwen (莫綺雯), aged 46, is our chief financial officer. She is mainly responsible for directing financial and accounting management.

Ms. Mo served as a deputy manager of the financial guidance department of our Company in April 2012 and was subsequently promoted to manager, a position she held until July 2019. From July 2019 to November 2025, she served as a deputy general supervisor of the financial management center. Since November 2025, Ms. Mo has been serving as our chief financial officer.

Ms. Mo obtained a master's degree in business administration from Harbin Institute of Technology (哈爾濱工業大學) in the PRC in June 2025.

OTHER INFORMATION IN RELATION TO OUR DIRECTORS AND SENIOR MANAGEMENT

As of the Latest Practicable Date, save as disclosed in "Appendix VII — Statutory and General Information — D. Further Information about Our Directors, Chief Executive and Substantial Shareholders — 1. Disclosure of Interest," each of our Directors did not have any interest in the Shares within the meaning of Part XV of the SFO.

Save as disclosed above, to the best knowledge, information and belief of our Directors having made all reasonable inquiries, there are no material matters relating to their appointment as a Director that need to be brought to the attention of our Shareholders and there is no other information in relation to his or her appointment which is required to be disclosed pursuant to Rule 13.51(2) of the Listing Rules as of the Latest Practicable Date.

Save as disclosed above, none of our Directors and senior management held any other directorships in any other company listed in Hong Kong or overseas during the three years immediately preceding the date of this document.

Save as disclosed above, none of our Directors and senior management is related to other Directors, senior management or substantial Shareholders of our Company.

JOINT COMPANY SECRETARIES

Dr. WU Shijun (吳士君) was appointed as one of the joint company secretaries of our Company with effect from [**REDACTED**]. For his biography, see "— Board of Directors — Executive Directors" in this section.

Ms. KWOK Yan Ting Jennis (郭恩廷) was appointed as one of the joint company secretaries of our Company with effect from April 23, 2026.

Ms. Kwok has over 12 years of extensive experience in corporate governance, company secretarial practice and regulatory compliance. She is currently a senior manager, entity solutions of Computershare Hong Kong Investor Services Limited. Ms. Kwok is a member of both The Hong Kong Chartered Governance Institute and The Chartered Governance Institute in the United Kingdom. She is also a holder of the practitioner's endorsement of The Hong Kong Chartered Governance Institute. In addition, she is a Certified Environmental, Social and Governance Analyst accredited by The European Federation of Financial Analysts Societies and a Certified ESG Planner awarded by the International Chamber of Sustainable Development. She holds the Sustainability and Climate Risk Certificate issued by the Global Association of Risk Professionals.

BOARD COMMITTEES

Our Company has established four committees under the Board in accordance with the relevant laws and regulations in Chinese Mainland, the Articles of Association and the Corporate Governance Code under the Listing Rules, including the Audit Committee, Nomination Committee, Remuneration and Assessment Committee and Strategy Committee.

Audit Committee

We have established an Audit Committee in compliance with Rule 3.21 of the Listing Rules and the Corporate Governance Code set out in Appendix C1 to the Listing Rules. The primary duties of the Audit Committee are to review and supervise our financial information disclosure, internal and external audit work and internal control system of our Group; and provide advice and comments to our Board. The Audit Committee comprises three independent non-executive Directors, namely, Ms. PENG Hui (彭慧), Mr. GAO Guolei (高國壘), and Dr. TIAN Suhua (田素華). Ms. PENG Hui (彭慧) is the chairperson of the Audit Committee, who holds the appropriate professional qualifications as required under Rules 3.10(2) and 3.21 of the Listing Rules.

Nomination Committee

We have established a Nomination Committee in compliance with Rule 3.27A of the Listing Rules and the Corporate Governance Code set out in Appendix C1 to the Listing Rules. The primary duties of the Nomination Committee are to assess the candidates and review selection criteria and procedures for Directors and senior management, and to make recommendations to our Board. The Nomination Committee comprises three independent non-executive Directors, namely, Mr. GAO Guolei (高國壘), Ms. PENG Hui (彭慧), and Dr. TIAN Suhua (田素華). Mr. GAO Guolei (高國壘) is the chairperson of the Nomination Committee.

Remuneration and Assessment Committee

We have established a Remuneration and Assessment Committee in compliance with Rule 3.25 of the Listing Rules and the Corporate Governance Code set out in Appendix C1 to the Listing Rules. The primary duties of the Remuneration and Assessment Committee are to review and make recommendations to our Board regarding the terms of remuneration packages, bonuses and other compensation payable to our Directors and senior management. The Remuneration and Assessment Committee comprises three independent non-executive Directors, namely, Dr. TIAN Suhua (田素華), Mr. GAO Guolei (高國壘), and Ms. PENG Hui (彭慧). Dr. TIAN Suhua (田素華) is the chairperson of the Remuneration and Assessment Committee.

Strategy Committee

We have established a Strategy Committee under the Board. The primary duties of the Strategy Committee are to make recommendations to our Board on the long-term development strategy and major investments and projects of our Company. The Strategy Committee comprises two executive Directors and one independent non-executive Director, namely, Mr. CHEN, Mr. LI and Dr. TIAN Suhua (田素華). Mr. CHEN is the chairperson of the Strategy Committee.

CORPORATE GOVERNANCE

We recognize the importance of incorporating elements of good corporate governance in our management structure and internal control procedures so as to achieve effective accountability. We intend to comply with all code provisions in the Part 2 of the Corporate Governance Code as set out in Appendix C1 to the Listing Rules after the [**REDACTED**].

BOARD DIVERSITY POLICY

Our Company has adopted a board diversity policy which sets out the approach to achieve diversity of the Board. We recognize and embrace the benefits of having a diverse Board and see increasing diversity at the Board level as an essential element in supporting the attainment of our Company's strategic objectives and sustainable development. Pursuant to the board diversity policy, in reviewing and assessing suitable candidates to serve as a director of our Company, the Nomination Committee will consider a number of factors, including but not limited to talent, skills, gender, age, cultural and educational background, ethnicity, professional experience, independence, knowledge and length of service. In particular, our Company currently has one female Director on the Board and will continue to work towards enhancing the gender diversity of the Board. Our Directors have a balanced mix of knowledge and skills, and we have three independent non-executive Directors, with different industry backgrounds. Taking into account our existing business model and specific needs as well as the different background of our Directors, the composition of our Board satisfies our Board diversity policy. Pursuant to the board diversity policy, after the [**REDACTED**], the Nomination Committee will discuss periodically and when necessary, agree on the measurable objectives for achieving diversity, including gender diversity, on the Board and recommend them to the Board for formal adoption.

MANAGEMENT PRESENCE IN HONG KONG

According to Rules 8.12 and 19A.15 of the Listing Rules, we must have sufficient management presence in Hong Kong. This normally means that at least two of our executive Directors must be ordinarily resident in Hong Kong. Since the principal business operations of our Group are conducted outside of Hong Kong, our Company does not and for the foreseeable future will not have a sufficient management presence in Hong Kong. We have applied for, and the Stock Exchange [has] granted us, a waiver from compliance with Rules 8.12 and 19A.15 of the Listing Rules. For details, see "Waivers and Exemption — Management Presence in Hong Kong."

REMUNERATION

Our Directors and senior management receive remuneration, including basic payments and performance-related payments, including fees, salaries and allowance, retirement benefit costs, discretional bonus, and share based payments. When reviewing and determining the specific remuneration packages for our Directors and members of the senior management of our Company, the Shareholders' meetings and the Board of Directors take into account factors such as salaries paid by comparable companies, time commitment, level of responsibilities, employment elsewhere in our Group and desirability of performance-based remuneration. As required by the relevant PRC laws and regulations, our Company also participates in various defined contribution plans organized by relevant provincial and municipal government authorities and welfare schemes for employees of our Company, including medical insurance, injury insurance, unemployment insurance, pension insurance, maternity insurance and housing provident fund.

For the years ended December 31, 2023, 2024 and 2025, the aggregate remuneration (including fees, salaries and allowance, retirement benefit costs, discretional bonus, and share based payments) paid to our Directors amounted to RMB6.23 million, RMB5.68 million and RMB6.13 million, respectively.

According to existing effective arrangements, we estimate the total remuneration before taxation to be accrued to our Directors in kind for their service for the financial year ending December 31, 2026 to be RMB4.51 million. The actual remuneration of our Directors in 2026 may be different from the expected remuneration.

For the years ended December 31, 2023, 2024 and 2025, the aggregate remuneration (including salaries and other emoluments, retirement scheme contributions) paid to our five highest paid individuals (excluding Directors) amounted to RMB29.14 million, RMB30.65 million and RMB43.06 million, respectively.

During the Track Record Period, (i) no remuneration was paid to our Directors or the five highest paid individuals as an inducement to join, or upon joining our Group, (ii) no compensation was paid to, or receivable by, our Directors or past Directors or the five highest paid individuals for the loss of office as director of any member of our Group or any other office in connection with the management of the affairs of any member of our Group and (iii) none of our Directors waived any remuneration.

Save as disclosed above, during the Track Record Period, no other payments have been made or are payable by our Group to our Directors and the five highest paid individuals.

CONFIRMATIONS FROM OUR DIRECTORS

Rule 3.09D of the Listing Rules

Each of our Directors confirms that he or she (i) has obtained the legal advice referred to under Rule 3.09D of the Listing Rules on May 19, 2026 and (ii) understands his or her obligations as a director of a [**REDACTED**] under the Listing Rules.

Rule 3.13 of the Listing Rules

Each of the independent non-executive Directors has confirmed (i) his or her independence as regards each of the factors referred to in Rules 3.13(1) to (8) of the Listing Rules, (ii) he or she has no past or present financial or other interest in the business of our Company or its subsidiaries or any connection with any core connected person of our Company under the Listing Rules as of the Latest Practicable Date and (iii) that there are no other factors that may affect his or her independence at the time of his or her appointments.

Rule 8.10 of the Listing Rules

Each of our Directors (other than our independent non-executive Directors) confirms that as of the Latest Practicable Date, he or she did not have any interest in a business which competes or is likely to compete, directly or indirectly, with our business and requires disclosure under Rule 8.10 of the Listing Rules.

COMPLIANCE ADVISOR

We have appointed Rainbow Capital (HK) Limited as our Compliance Advisor pursuant to Rule 3A.19 of the Listing Rules. Our Compliance Advisor will provide us with guidance and advice as to compliance with the Listing Rules and applicable Hong Kong laws. Pursuant to Rule 3A.23 of the Listing Rules, our Compliance Advisor will advise our Company in certain circumstances including:

(a) before the publication of any regulatory announcement, circular, or financial report;

(b) where a transaction, which might be a notifiable or connected transaction, is contemplated, including share issues, sales or transfers of treasury shares and share repurchases; and

(c) where we propose to use the [**REDACTED**] of the [**REDACTED**] in a manner different from that detailed in this document or where the business activities, development or results of our Group deviate from any forecast, estimate or other information in this document; and where the Stock Exchange makes an inquiry to our Company regarding unusual movements in the price or trading volume of its listed securities or any other matters in accordance with Rule 13.10 of the Listing Rules.

Pursuant to Rule 3A.24 of the Listing Rules, the Compliance Advisor will, on a timely basis, inform our Company of any amendment or supplement to the Listing Rules that are announced by the Stock Exchange. The Compliance Advisor will also inform our Company of any new or amended law, regulation or code in Hong Kong applicable to us and advise us on the applicable requirements under the Listing Rules and laws and regulations.

The term of appointment of our Compliance Advisor shall commence on the [**REDACTED**] and is expected to end on the date on which we comply with Rule 13.46 of the Listing Rules in respect of our financial results for the first full financial year commencing after the [**REDACTED**].